SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,366,684,616.305855 in circulation. The last known price of Stellar is 0.15346137 USD and is down -1.11 over the last 24 hours. It is currently trading on 848 active market(s) with $109,670,947.94 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLMs continued selloff and failure to sustain rebounds dominate the discussion, with bearish traders blaming persistent supply and underperformance while bulls frame the decline as a buying opportunity. The debate also centers on whether institutional tokenization developments, including the anticipated DTCC integration, can drive token demand despite community concerns that adoption has not translated into price strength.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Discussion centers on Cathie Woods portfolio decisions and ARKKs performance, with many traders criticizing its volatility, frequent rotations, and long-term lag versus broad tech benchmarks. Others see signs of a technical recovery and renewed strength in growth stocks, so sentiment remains divided.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Clorox drew attention after quarterly earnings and revenue beat expectations, while its full-year outlook was maintained. Traders are weighing the results against a technical recovery, noting a reclaim of the 50-week average and watching for a breakout from a long-term falling wedge; some remain cautious about whether the rebound can hold.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix is drawing attention around ASH 2026 abstracts and an oral presentation featuring NXC-201 data from the NEXICART-2 trial in relapsed or refractory AL amyloidosis. Traders are emphasizing the reported deep responses and favorable safety profile, while some remain cautious about the stocks volatility and the path to a BLA.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 10.81338038 USD and is down -0.11 over the last 24 hours. It is currently trading on 2314 active market(s) with $248,679,031.17 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

A rally in LINK and reports of elevated trading volume have fueled breakout talk, with traders citing an AI launch and institutional tokenization integrations as bullish drivers. Skeptics point to repeated resistance failures and question whether adoption announcements will translate into token demand.

ETF Opportunities Trust - Roundhill T-REX 2X Long DRAM Daily Target ETF

T-REX 2X Long DRAM Daily Target ETF

RAMs sharp swings as a 2 daily leveraged DRAM ETF are driving discussion, with traders connecting its moves to Korean memory stocks and broader semiconductor sentiment. The community is split between an AI-driven memory-demand recovery thesis and concerns about steep losses, leverage-related volatility, and tracking mismatches with DRAM.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs role arranging and distributing financing for AI infrastructure is drawing attention as traders weigh fee income from the buildout against concerns that debt-funded spending and uncertain returns could raise credit risk. The community is split between seeing Goldman as a beneficiary of continued AI investment and viewing its shares weakness and put-heavy options activity as signs of caution.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Traders are focused on whether Salesforce can monetize AI agents when the technology is also pitched as reducing the employee seats that underpin traditional software subscriptions; concerns about renewal budgets and customers questioning AI add-on costs are fueling bearish sentiment. The debate is speculative, with some traders watching technical support and arguing the selloff may be a buying opportunity.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyxs Q3 updatealongside a workforce reduction and deeper spending cuts while reaffirming its 2027 profitability goalis driving discussion. Traders are split on whether cost discipline and new gene-therapy launches can offset the earnings shortfall and pipeline setbacks.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X ETF

Direxion Daily TSLA Bull 2X Shares

Sharp swings in Tesla have put TSLL in focus, with its 2x daily leverage amplifying both losses and rebounds. Traders are divided between buying an oversold dip and warning that continued volatility and leverage decay could prolong losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The dominant discussion is speculation that Johnson & Johnson could acquire Sellas Life Sciences for its oncology assets, with traders pointing to an alleged strategic fit and circumstantial clues; no deal has been confirmed. Some traders also cite J&Js positive early prostate-cancer data as a bullish catalyst.

Johnson & Johnson announces ICOTYDE (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide

Johnson & Johnson announces ICOTYDE (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide Johnson & Johnson announces ICOTYDE (icotrokinra) delivers significant improvement in psoriatic arthritis...

Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjgren's disease that reveal insights on importance of symptom improvements most valued by patients

Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjgren's disease that reveal insights on importance of symptom improvements most valued by patients Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjgren's disease that reveal insights on importance of symptom...

First Therapy for Advanced Head & Neck Cancer in 10 Years: Johnson & Johnson Secures Accelerated FDA Nod

Johnson & Johnson wins FDA accelerated approval for RYBREVANT FASPRO to treat recurrent or metastatic head and neck cancer.read more...

JNJ's Innovative Medicine Unit Grows in Q3 Despite Patent Losses

J&J's Innovative Medicine sees a 7.7% rise in Q3 sales to $16.76 billion, as blockbuster drugs and new launches offset generic headwinds.

Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJPR NewswireNEW YORK, Nov. 5, 2026 NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is...

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as First and Only...

BAYRY vs. JNJ: Which Stock Is the Better Value Option?

BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays Weak

Boston Scientific's cyber disruption cuts Q3 growth and earnings, forcing lower 2026 guidance as management sees 2027 as the cycle's trough.

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets 

Equity

ASH will release regular meeting abstracts on Wednesday, followed by late-breaking abstracts on Dec.7.

Johnson & Johnson raised 2026 estimated reported sales guidance to $101B$101.4B, with midpoint $101.2B, and adjusted EPS guidance to $11.05$11.15, midpoint $11.10, or 7.4% and 2.9% at midpoint.

Johnson & Johnsons adjusted EPS and adjusted net earnings declined; STELARA, SIMPONI/SIMPONI ARIA, and REMICADE partially offset Innovative Medicine growth; reported net earnings were $210M and EPS reflected a one-time talc litigation charge.

Johnson & Johnson raised 2026 sales and adjusted EPS guidance; OTTAVA received U.S. FDA market authorization and IMAAVY approval; Innovative Medicine operational sales grew 7.9% with named products among its growth drivers.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Bearish Sentiment

<ul class="summary-bullets"><li>Investors are watching for possible SLS009 updates as Sellas expects Q4 topline results from its Phase 2 study in newly diagnosed AML.</li><li>Sellas has a 600-square-foot booth at the Dec.12 to Dec.15 ASH meeting in New Orleans, in the same hall as several major drugmakers.</li><li>Q3 holdings disclosures showed stake increases by Pictet, Swiss Life, Arizona State Retirement System and Xponance.</li></ul>Shares of Sellas Life Sciences (SLS) snapped a four-day losing streak on Tuesday as retail investors looked ahead to abstracts from the American Society of Hematology (ASH), while fresh filings revealed increased holdings by Swiss asset managers and Arizona State Retirement System.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped nearly 4% on Tuesday to $8.70.&nbsp;<h2 class="st-heading-2">SLS Bulls Count Down To ASH Abstracts</h2>ASH will release regular meeting abstracts on Wednesday, with late-breaking abstracts following on Dec.7.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.hematology.org/Meetings/Annual-Meeting/Abstracts?utm_source=chatgpt.com">&nbsp;</a>Sellas investors are watching for possible updates on SLS009, or Tambiciclib, its CDK9 inhibitor being studied in acute myeloid leukemia (AML). In August, Sellas said it expected fourth-quarter topline results from its Phase 2 study of SLS009 in newly diagnosed AML.&nbsp;The releases set the stage for the 68th ASH Annual Meeting and Exposition, running Dec.12 to Dec.15 in New Orleans. The event brings together blood-disease specialists, researchers and drugmakers, with more than 275 exhibitors expected.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.hematology.org/meetings/annual-meeting?utm_source=chatgpt.com">&nbsp;</a>Sellas has a 600-square-foot booth at the far end of Hall G, directly beside the poster area. Its 20-by-30-foot space, Booth 138, puts it in the same hall as large exhibits from Eli Lilly, Takeda, Genentech and AstraZeneca.&nbsp;Pfizer, Merck, Sanofi, AbbVie and Bristol Myers Squibb have booths across other halls, while Johnson &amp; Johnson is in Hall J, farther from Sellas. The broader exhibitor lineup includes GSK, Novartis, Amgen, Novo Nordisk, Daiichi Sankyo, Astellas, and Gilead and Kite Oncology.<h2 class="st-heading-2">Swiss Managers And Arizona Pension Raise Stakes</h2>Several institutional investors increased their stakes in Sellas during the third quarter, according to Sept.30 holdings disclosed in Tuesday filings tracked by Fiscal.ai.Pictet Asset Management Holding SA raised its stake by 15%, adding 3,704 shares to hold 27,688. Swiss Life Asset Management increased its stake by nearly 10%, adding 1,168 shares to bring its total to 13,292.Meanwhile, Arizona State Retirement System added 5,839 shares, lifting its holding by 12% to 55,391. Xponance increased its position by 3% to 19,025 shares.<h2 class="st-heading-2">Sellas’ Regal Enters Final Analysis Stage</h2>Sellas announced last week that its Phase 3 Regal trial had reached the prespecified 80th event, or death, clearing the way for database lock, unblinding and final statistical analysis.The randomized trial is testing Galinpepimut-S (GPS) as maintenance treatment for AML patients in second complete remission. Its primary endpoint is overall survival. “Reaching the 80th event represents a critical milestone in the REGAL trial,” CEO Angelos Stergiou said. Sellas expects preliminary topline results this quarter but has not set a release date.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS jumped to ‘extremely bullish’ from ‘bullish’ levels a day ago amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_732ac022d2.png" alt="sls ss.png" width="643" height="340"><figcaption>SLS sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Bio_buyout/message/668064034">anticipates</a> SLS009 data in the abstract release and said that the drug’s potential “should alone be 5X our current market Cap.” Another user&nbsp;<a href="https://stocktwits.com/Ewebb1018/message/668061540">said</a>, “it is not far fetched to think we may see data relating to GPS Expanded Access Program, and even more likely to see data regarding SLS-009.”<stembedurl>https://stocktwits.com/Ewebb1018/message/668061540</stembedurl>A separate trader also&nbsp;<a href="https://stocktwits.com/Cheffinance/message/668061442">distinguished</a> the ASH release from the pending Regal readout. “tomorrow they can say something about sls009, not about regal”<a href="https://stocktwits.com/Cheffinance/message/668061442">&nbsp;</a><stembedurl>https://stocktwits.com/Cheffinance/message/668061442</stembedurl>Institutional ownership also drew attention. “Institutions just keep loading up,” another user&nbsp;<a href="https://stocktwits.com/robcarroll/message/668067161">said</a>.<stembedurl>https://stocktwits.com/robcarroll/message/668067161</stembedurl>SLS stock has risen 135% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/super-micro-s-q1-revenue-nearly-quadruples-to-20-b-on-surging-ai-server-demand/cNGhsPWR9dk">Super Micro’s Q1 Revenue Nearly Quadruples To $20B On Surging AI Server Demand&nbsp;</a>

In this photo illustration, the SELLAS Life Sciences Group logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

Abbvie Inc

AMGEN Inc.

Bristol-Myers Squibb Co.

Glaxosmithkline plc - ADR

iShares Biotechnology ETF

Lilly(Eli) & Co

Merck & Co Inc

Novo Nordisk A/S

Novartis AG

Pfizer Inc

SELLAS Life Sciences Group Inc

Sanofi-Aventis

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Futures

Fundamentals

Info

JNJ Futures

JNJ Single Stock Futures